Rich66
10-18-2009, 01:39 PM
http://clinicaltrials.gov/ct2/show/study/NCT00429182?term=cancer+stem+cell&rank=20&show_desc=Y#desc
Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer
This study is currently recruiting participants.
Verified by M.D. Anderson Cancer Center, May 2009
First Received: January 29, 2007 Last Updated: May 27, 2009 History of Changes (http://clinicaltrials.gov/ct2/archive/NCT00429182)
Sponsored by: M.D. Anderson Cancer Center
Information provided by: M.D. Anderson Cancer Center ClinicalTrials.gov Identifier: NCT00429182
http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif Purpose Primary Objectives:
To determine whether high-dose chemotherapy (HDCT) with purged autologous stem cell products will reduce the presence of circulating tumor cells (CTCs) among metastatic breast cancer (MBC) patients after receiving high-dose chemotherapy autologous hematopoietic stem cell transplantation.
To determine whether reduction of CTCs will correlate with prolonged progression-free survival (PFS).
Secondary Objectives:
To determine whether reduction of CTCs will correlate with prolonged overall survival (OS).
To characterize the biology of CTC.
Condition (http://clinicaltrials.gov/ct2/help/conditions_desc) Intervention (http://clinicaltrials.gov/ct2/help/interventions_desc) Phase (http://clinicaltrials.gov/ct2/help/phase_desc) Breast Cancer
Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Thiotepa
Procedure: Stem Cell Transplant
Phase II
Study Type: Interventional Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study Official Title: Phase II Study of Purging of Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer Patients
Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer
This study is currently recruiting participants.
Verified by M.D. Anderson Cancer Center, May 2009
First Received: January 29, 2007 Last Updated: May 27, 2009 History of Changes (http://clinicaltrials.gov/ct2/archive/NCT00429182)
Sponsored by: M.D. Anderson Cancer Center
Information provided by: M.D. Anderson Cancer Center ClinicalTrials.gov Identifier: NCT00429182
http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif Purpose Primary Objectives:
To determine whether high-dose chemotherapy (HDCT) with purged autologous stem cell products will reduce the presence of circulating tumor cells (CTCs) among metastatic breast cancer (MBC) patients after receiving high-dose chemotherapy autologous hematopoietic stem cell transplantation.
To determine whether reduction of CTCs will correlate with prolonged progression-free survival (PFS).
Secondary Objectives:
To determine whether reduction of CTCs will correlate with prolonged overall survival (OS).
To characterize the biology of CTC.
Condition (http://clinicaltrials.gov/ct2/help/conditions_desc) Intervention (http://clinicaltrials.gov/ct2/help/interventions_desc) Phase (http://clinicaltrials.gov/ct2/help/phase_desc) Breast Cancer
Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Thiotepa
Procedure: Stem Cell Transplant
Phase II
Study Type: Interventional Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study Official Title: Phase II Study of Purging of Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer Patients